Finally, the multi-kinase inhibitor ponatinib in combination with azacitidine demonstrated a durable ORR of 52% in unfit newly diagnosed patients with FLT3-mutated AML [63, 64]. This evidence concerns the gene FLT3 and acute myeloid leukemia.